Clinical Trial Update: Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of berzosertib with irinotecan for TP53-mutant advanced gastric or gastroesophageal junction cancer; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Berzosertib (berzosertib)
• Irinotecan (Irinotecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-08